# Veru Inc. (VERU)

Source: https://www.quantisnow.com/company/VERU
Generated: 2026-11-15T17:19:25.638Z

- Ticker: VERU
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0000863894
- Website: verupharma.com

## About

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include VERU-111, an oral chemical entity that is being evaluated in open label Phase 1b and Phase 2 clinical trials in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer, as well as being evaluated in a Phase 2 clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome; and for the treatment of taxane resistant metastatic triple negative breast cancer. Its drug candidates also comprise VERU-100, a gonadotropin-releasing hormone antagonist peptide formulation to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. In addition, the company's drug candidates include Enobosarm, an oral selective androgen receptor agonist that targets the androgen receptor positive, estrogen receptor positive, and human epidermal growth factor receptor 2 metastatic breast cancer without the unwanted virilizing side effects. Further, it is advancing a new drug formulation in its specialty pharmaceutical pipeline addressing unmet medical needs in urology, such as Tadalafil and Finasteride Combination. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. is headquartered in Miami, Florida.

## Latest VERU news and filings

- 2026-11-09 13:30 UTC [Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026](https://www.quantisnow.com/insight/veru-to-present-new-results-on-effects-of-enobosarm-on-6780496)
- 2026-09-08 12:17 UTC [SEC Form 8-K] [SEC Form 8-K filed by Veru Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-veru-inc-6707629)
- 2026-09-08 12:17 UTC [Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial](https://www.quantisnow.com/insight/veru-advances-oral-sabizabulin-following-positive-preclinical-data-showing-potent-6707626)
- 2026-09-02 12:30 UTC [Conference Announcement] [Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference](https://www.quantisnow.com/insight/veru-to-participate-in-fireside-chat-at-the-2026-cantor-6702469)
- 2026-08-17 20:26 UTC [Insider Buy] [Chief Scientific Officer Barnette K Gary bought $4,842 worth of shares (1,800 units at $2.69), increasing direct ownership by 360% to 2,300 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-barnette-k-gary-bought-4842-worth-of-6685107)
- 2026-08-10 12:51 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Veru Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-veru-inc-6672975)
- 2026-08-10 11:00 UTC [SEC Form 8-K] [Veru Inc. filed SEC Form 8-K: Results of Operations and Financial Condition](https://www.quantisnow.com/insight/veru-inc-filed-sec-form-8-k-results-of-operations-and-6672597)
- 2026-08-10 10:30 UTC [Earnings Date] [Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress](https://www.quantisnow.com/insight/veru-reports-fiscal-2026-third-quarter-financial-results-and-phase-6672504)
- 2026-08-04 12:30 UTC [Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss](https://www.quantisnow.com/insight/veru-announces-notice-of-allowance-for-key-methods-of-use-6661292)
- 2026-08-03 12:30 UTC [Earnings Date] [Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th](https://www.quantisnow.com/insight/veru-to-report-fiscal-2026-third-quarter-financial-results-on-6658850)
- 2026-07-30 12:30 UTC [Conference Announcement] [Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference](https://www.quantisnow.com/insight/veru-to-participate-in-fireside-chat-at-the-canaccord-genuitys-6655247)
- 2026-07-27 12:10 UTC [Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss](https://www.quantisnow.com/insight/veru-announces-full-enrollment-for-phase-2b-plateau-clinical-trial-6649076)
- 2026-07-07 12:30 UTC [Conference Announcement] [Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day](https://www.quantisnow.com/insight/veru-to-present-at-2026-obesity-weight-loss-drug-development-6629553)
- 2026-07-02 20:08 UTC [SEC Form 8-K] [SEC Form 8-K filed by Veru Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-veru-inc-6625245)
- 2026-07-02 20:05 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Veru Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-veru-inc-6625145)
- 2026-06-04 12:30 UTC [SEC Form 8-K] [Veru Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/veru-inc-filed-sec-form-8-k-other-events-6588709)
- 2026-05-13 13:19 UTC [SEC Form S-8] [SEC Form S-8 filed by Veru Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-veru-inc-6550069)
- 2026-05-13 13:09 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Veru Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-veru-inc-6550038)
- 2026-05-13 11:00 UTC [SEC Form 8-K] [Veru Inc. filed SEC Form 8-K: Results of Operations and Financial Condition](https://www.quantisnow.com/insight/veru-inc-filed-sec-form-8-k-results-of-operations-and-6549587)
- 2026-05-13 10:30 UTC [Earnings Date] [Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress](https://www.quantisnow.com/insight/veru-reports-fiscal-2026-second-quarter-financial-results-and-phase-6549485)
- 2026-05-06 21:10 UTC [SEC Form 4] [SEC Form 4 filed by President and CEO Steiner Mitchell Shuster](https://www.quantisnow.com/insight/sec-form-4-filed-by-president-and-ceo-steiner-mitchell-6536368)
- 2026-05-06 20:59 UTC [SEC Form 4] [SEC Form 4 filed by Chief Admin Officer and CFO Greco Michele](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-admin-officer-and-cfo-6536253)
- 2026-05-06 20:45 UTC [SEC Form 4] [SEC Form 4 filed by Director Katzovitz Loren Mark](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-katzovitz-loren-mark-6536156)
- 2026-05-06 20:34 UTC [SEC Form 4] [SEC Form 4 filed by Director Hyun Grace](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-hyun-grace-6536060)
- 2026-05-06 20:20 UTC [SEC Form 4] [SEC Form 4 filed by Director Rankowitz Michael L](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-rankowitz-michael-l-6535814)
- 2026-05-06 20:10 UTC [SEC Form 4] [SEC Form 4 filed by Director Lu Lucy](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-lu-lucy-6535490)
- 2026-05-06 19:59 UTC [SEC Form 4] [SEC Form 4 filed by Chief Scientific Officer Barnette K Gary](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-scientific-officer-barnette-k-6535055)
- 2026-05-06 19:43 UTC [SEC Form 4] [SEC Form 4 filed by Chief Corporate Officer Fisch Harry](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-corporate-officer-fisch-harry-6535028)
- 2026-05-06 12:30 UTC [Earnings Date] [Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th](https://www.quantisnow.com/insight/veru-to-report-fiscal-2026-second-quarter-financial-results-on-6534240)
- 2026-04-16 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Veru Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-veru-inc-6502012)
- 2026-04-16 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Veru Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-veru-inc-6501998)
- 2026-04-07 20:18 UTC [SEC Form S-3] [SEC Form S-3 filed by Veru Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-veru-inc-6491384)
- 2026-04-07 20:11 UTC [SEC Form S-3] [SEC Form S-3 filed by Veru Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-veru-inc-6491286)
- 2026-03-13 20:04 UTC [SEC Form 8-K] [Veru Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/veru-inc-filed-sec-form-8-k-leadership-update-submission-of-6446858)
- 2026-03-09 12:30 UTC [Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss](https://www.quantisnow.com/insight/veru-enrolls-first-patient-in-phase-2b-plateau-clinical-trial-6436381)
- 2026-02-19 13:30 UTC [Conference Announcement] [Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference](https://www.quantisnow.com/insight/veru-to-present-at-the-oppenheimer-36th-annual-healthcare-life-6401529)
- 2026-02-11 15:32 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Veru Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-veru-inc-6386039)
- 2026-02-11 12:00 UTC [SEC Form 8-K] [Veru Inc. filed SEC Form 8-K: Results of Operations and Financial Condition](https://www.quantisnow.com/insight/veru-inc-filed-sec-form-8-k-results-of-operations-and-6385557)
- 2026-02-11 11:30 UTC [Earnings Date] [Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress](https://www.quantisnow.com/insight/veru-reports-fiscal-2026-first-quarter-financial-results-and-clinical-6385457)
- 2026-02-04 13:30 UTC [Earnings Date] [Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th](https://www.quantisnow.com/insight/veru-to-report-fiscal-2026-first-quarter-financial-results-on-6374383)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/VERU
- Earnings history: https://www.quantisnow.com/earnings/VERU
- Dividend history: https://www.quantisnow.com/dividends/VERU
- Insider transactions: https://www.quantisnow.com/insiders/VERU
- Options chain: https://www.quantisnow.com/options/VERU
- SEC 8-K filings only: https://www.quantisnow.com/company/VERU/8-k
- RSS and alerts for VERU: https://www.quantisnow.com/docs/rss-feeds.md